Bronhopulmonalna displazija
DOI:
https://doi.org/10.5457/ams.v47iSup%201.416Keywords:
bronchopulmonary dysplasia, infantsAbstract
Bronchopulmonary dysplasia (BDP) is a chronic lung disease which is defined as the need to apply oxygen therapy 28 days of postnatal life and the degree of severity of the disease is determined 36 weeks corrected gestational age (KGS). It is a chronic lung disease whose symptoms and signs are derived from the neonatal period and is one of the most severe consequences of preterm labor, leading to extended and fixed depending on the application and oxygen influences the mortality and morbidity in preterm infants. The pathological process in pulmonary hemorrhage and affects the airways and lung parenchyma and usually occurs in small premature infants with respiratory distress syndrome which leads to lung injury and inadequate reparations such damage. Frequency of GDP ranges from 4-53%. Risk factors for the development of bronchopulmonary dysplasia can be podlijediliti on prenatal and postnatal. The criteria for determining the severity of BPD vary for infants who are born before or after 32 gestational weeks. Given that the GDP chronic lung disease can last for weeks and months but they certainly need to be patient and not expect rapid improvement after therapy administered.
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
